Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05280602 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PF-05280602 | BIOLOGICAL | 0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose |
PF-05280602 is an investigational monoclonal antibody being developed for the treatment of Hemophilia A, a bleeding disorder. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
PF-05280602 is being developed by Gyre Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol GYRE.
PF-05280602 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. One Phase 1 trial has been completed.
PF-05280602 has one completed clinical trial, identified as NCT01439971. This Phase 1 study evaluated the safety, pharmacokinetics, and pharmacodynamics of the drug in adult subjects with Hemophilia A, enrolling 29 participants.
PF-05280602 is associated with a recombinant Factor VIIa variant known as 813d. The completed clinical trial NCT01439971 studied this variant in subjects with Hemophilia A, indicating that PF-05280602 and the variant are related.